论文部分内容阅读
36例新诊断的T2DM患者随机分为甘精胰岛素联合那格列奈(glar+Na)组和甘精胰岛素加三餐前短效胰岛素(glar+RI)组各18例,疗程3周,两组的差异无统计学意义(P>0.05)。结果glar+Na组和glar+RI组FPG、2hPG较治疗前明显下降,FC-P、2hC-P较治疗前升高(P<0.05)。所需时间以及低血糖发生率无统计学差异(P>0.05)。结论HbA1c>9%的新诊断T2DM患者两种短期强化方案疗效均佳,有效控制高血糖,glar+Na组费用支出少,依从性更高,适合不愿住院者在门诊治疗。
Thirty-six newly diagnosed T2DM patients were randomly divided into glar + Na group and glargine group plus glar + RI group for 18 weeks for 3 weeks. There was no significant difference between groups (P> 0.05). Results The levels of FPG and 2hPG in glar + Na group and glar + RI group were significantly lower than those before treatment, and the levels of FC-P and 2hC-P were higher than those before treatment (P <0.05). The time required and the incidence of hypoglycemia was not statistically different (P> 0.05). Conclusions Both short-term intensive regimens with HbA1c> 9% in newly diagnosed T2DM patients are effective in controlling hyperglycemia. The patients in glar + Na group have less expenses and higher compliance, which is suitable for outpatients who do not want to be hospitalized.